CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) and ProKidney (NASDAQ:PROK – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.
Analyst Recommendations
This is a summary of recent ratings and price targets for CytomX Therapeutics and ProKidney, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CytomX Therapeutics | 1 | 1 | 9 | 1 | 2.83 |
| ProKidney | 1 | 0 | 1 | 1 | 2.67 |
CytomX Therapeutics currently has a consensus price target of $11.90, indicating a potential upside of 374.10%. ProKidney has a consensus price target of $12.00, indicating a potential upside of 733.33%. Given ProKidney’s higher probable upside, analysts clearly believe ProKidney is more favorable than CytomX Therapeutics.
Valuation & Earnings
This table compares CytomX Therapeutics and ProKidney”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CytomX Therapeutics | $76.20 million | 7.18 | -$17.37 million | ($0.50) | -5.02 |
| ProKidney | $890,000.00 | 489.15 | -$68.99 million | ($0.55) | -2.62 |
CytomX Therapeutics has higher revenue and earnings than ProKidney. CytomX Therapeutics is trading at a lower price-to-earnings ratio than ProKidney, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares CytomX Therapeutics and ProKidney’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CytomX Therapeutics | -435.21% | -38.46% | -30.33% |
| ProKidney | -10,288.39% | N/A | -27.39% |
Risk & Volatility
CytomX Therapeutics has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.
Insider & Institutional Ownership
67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 51.6% of ProKidney shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by company insiders. Comparatively, 39.8% of ProKidney shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
CytomX Therapeutics beats ProKidney on 8 of the 14 factors compared between the two stocks.
About CytomX Therapeutics
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
About ProKidney
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
